Irritable Bowel Syndrome (IBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Publisher Name » GlobalData
Published Date » 2011-09-12
No. Of Pages » 94
GlobalData, the industry analysis specialist, has released its new report, Irritable Bowel Syndrome (IBS) Therapeutics Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Irritable Bowel Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Irritable Bowel Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Irritable Bowel Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Irritable Bowel Syndrome Therapeutics market. Its scope includes
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Irritable Bowel Syndrome Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Irritable Bowel Syndrome Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Irritable Bowel Syndrome Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Irritable Bowel Syndrome Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Irritable Bowel Syndrome Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Irritable Bowel Syndrome Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Whats the next big thing in the global Irritable Bowel Syndrome Therapeutics market landscape? Identify, understand and capitalize.
Table of Content
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Irritable Bowel Syndrome (IBS) Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 7
2.3 Etiology 9
2.4 Pathophysiology 9
2.4.1 Visceral Hyperalgesia 9
2.4.2 Psychopathology 10
2.5 Symptoms 10
2.6 Diagnosis 10
2.6.1 Commonly Used Diagnosis Tests 12
2.7 Treatment and Management Options 13
2.7.1 Treatment for Lifestyle and Dietary Modifications 13
2.7.2 Treatment for Diarrhea and Constipation 13
2.7.3 Treatment for Pain or Bloating 13
2.8 GlobalData Pipeline Report Guidance 15
2.1 Overview 7
2.2 Epidemiology 7
2.3 Etiology 9
2.4 Pathophysiology 9
2.4.1 Visceral Hyperalgesia 9
2.4.2 Psychopathology 10
2.5 Symptoms 10
2.6 Diagnosis 10
2.6.1 Commonly Used Diagnosis Tests 12
2.7 Treatment and Management Options 13
2.7.1 Treatment for Lifestyle and Dietary Modifications 13
2.7.2 Treatment for Diarrhea and Constipation 13
2.7.3 Treatment for Pain or Bloating 13
2.8 GlobalData Pipeline Report Guidance 15
3 Irritable Bowel Syndrome (IBS) Therapeutics: Market Characterization 16
3.1 IBS Therapeutics Market Size (20052010) Global 16
3.2 IBS Therapeutics Market Forecast (20102018) Global 17
3.3 IBS Therapeutics Market Size (20052010) The US 18
3.4 IBS Therapeutics Market Forecast (20102018) The US 19
3.5 IBS Therapeutics Market Size (20052010) France 21
3.6 IBS Therapeutics Market Forecast (20102018) France 22
3.7 IBS Therapeutics Market Size (20052010) Germany 23
3.8 IBS Therapeutics Market Forecast (20102018) Germany 24
3.9 IBS Therapeutics Market Size (20052010) Italy 25
3.10 IBS Therapeutics Market Forecast (20102018) Italy 26
3.11 IBS Therapeutics Market Size (20052010) Spain 27
3.12 IBS Therapeutics Market Forecast (20102018) Spain 28
3.13 IBS Therapeutics Market Size (20052010) The UK 29
3.14 IBS Therapeutics Market Forecast (20102018) The UK 30
3.15 IBS Therapeutics Market Size (20052010) Japan 31
3.16 IBS Therapeutics Market Forecast (20102018) Japan 32
3.17 Drivers and Barriers for the IBS Therapeutics Market 33
3.17.1 Drivers for the IBS Therapeutics Market 33
3.17.2 Barriers for the IBS Therapeutics Market 33
3.18 Opportunity and Unmet Need Analysis 34
3.19 Key Takeaway 38
3.1 IBS Therapeutics Market Size (20052010) Global 16
3.2 IBS Therapeutics Market Forecast (20102018) Global 17
3.3 IBS Therapeutics Market Size (20052010) The US 18
3.4 IBS Therapeutics Market Forecast (20102018) The US 19
3.5 IBS Therapeutics Market Size (20052010) France 21
3.6 IBS Therapeutics Market Forecast (20102018) France 22
3.7 IBS Therapeutics Market Size (20052010) Germany 23
3.8 IBS Therapeutics Market Forecast (20102018) Germany 24
3.9 IBS Therapeutics Market Size (20052010) Italy 25
3.10 IBS Therapeutics Market Forecast (20102018) Italy 26
3.11 IBS Therapeutics Market Size (20052010) Spain 27
3.12 IBS Therapeutics Market Forecast (20102018) Spain 28
3.13 IBS Therapeutics Market Size (20052010) The UK 29
3.14 IBS Therapeutics Market Forecast (20102018) The UK 30
3.15 IBS Therapeutics Market Size (20052010) Japan 31
3.16 IBS Therapeutics Market Forecast (20102018) Japan 32
3.17 Drivers and Barriers for the IBS Therapeutics Market 33
3.17.1 Drivers for the IBS Therapeutics Market 33
3.17.2 Barriers for the IBS Therapeutics Market 33
3.18 Opportunity and Unmet Need Analysis 34
3.19 Key Takeaway 38
4 Irritable Bowel Syndrome (IBS) Therapeutics: Competitive Assessment 39
4.1 Overview 39
4.1.1 Strategic Competitor Assessment 39
4.2 Irritable Bowel Syndrome (IBS) Therapeutics Market Marketed Products Profile 41
4.2.1 Lotronex (alosetron) 41
4.2.2 Amitiza (lubiprostone) 44
4.2.3 Bentyl (dicyclomine hydrochloride) 45
4.2.4 Irribow (ramosetron hydrochloride) 47
4.3 Key Takeaway 48
4.1 Overview 39
4.1.1 Strategic Competitor Assessment 39
4.2 Irritable Bowel Syndrome (IBS) Therapeutics Market Marketed Products Profile 41
4.2.1 Lotronex (alosetron) 41
4.2.2 Amitiza (lubiprostone) 44
4.2.3 Bentyl (dicyclomine hydrochloride) 45
4.2.4 Irribow (ramosetron hydrochloride) 47
4.3 Key Takeaway 48
5 Irritable Bowel Syndrome (IBS) Therapeutics: Pipeline Assessment 49
5.1 Overview 49
5.2 Strategic Pipeline Assessment 49
5.3 IBS Pipeline Analysis Pipeline by Clinical Phases of Development 50
5.3.1 IBS Therapeutics NDA Filed 50
5.3.2 IBS Therapeutics Phase III Clinical Pipeline 50
5.3.3 IBS Therapeutics Phase II/Phase III Clinical Pipeline 51
5.3.4 IBS Therapeutics Phase II Clinical Pipeline 51
5.3.5 IBS Therapeutics Phase I Clinical Pipeline 51
5.3.6 IBS Therapeutics Preclinical Pipeline 52
5.3.7 IBS Therapeutics Discovery Pipeline 52
5.4 IBS Therapeutics Market Clinical Pipeline by Mechanism of Action 53
5.5 IBS Therapeutics, Other Promising MOA 54
5.6 IBS Technology Trends Analytical Framework 55
5.7 IBS Therapeutics Promising Drugs Under Clinical Development 57
5.8 Molecule Profile for Promising Drugs Under Clinical Development 58
5.8.1 Xifaxan (rifaximin) 58
5.8.2 Linaclotide 59
5.8.3 Asimadoline 60
5.8.4 Dexloxiglumide (loxiglumide-R isomer) 61
5.1 Overview 49
5.2 Strategic Pipeline Assessment 49
5.3 IBS Pipeline Analysis Pipeline by Clinical Phases of Development 50
5.3.1 IBS Therapeutics NDA Filed 50
5.3.2 IBS Therapeutics Phase III Clinical Pipeline 50
5.3.3 IBS Therapeutics Phase II/Phase III Clinical Pipeline 51
5.3.4 IBS Therapeutics Phase II Clinical Pipeline 51
5.3.5 IBS Therapeutics Phase I Clinical Pipeline 51
5.3.6 IBS Therapeutics Preclinical Pipeline 52
5.3.7 IBS Therapeutics Discovery Pipeline 52
5.4 IBS Therapeutics Market Clinical Pipeline by Mechanism of Action 53
5.5 IBS Therapeutics, Other Promising MOA 54
5.6 IBS Technology Trends Analytical Framework 55
5.7 IBS Therapeutics Promising Drugs Under Clinical Development 57
5.8 Molecule Profile for Promising Drugs Under Clinical Development 58
5.8.1 Xifaxan (rifaximin) 58
5.8.2 Linaclotide 59
5.8.3 Asimadoline 60
5.8.4 Dexloxiglumide (loxiglumide-R isomer) 61
6 Irritable Bowel Syndrome (IBS) Therapeutics: Clinical Trials Mapping 63
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 63
6.2 Clinical Trials by Phase 64
6.3 Clinical Trials by Trial Status 65
6.4 Clinical Trials Mapping by Sponsors 66
6.5 Clinical Trials Mapping by Prominent Sponsors 67
6.6 Participants in Therapeutic Clinical Trials Companies 68
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 63
6.2 Clinical Trials by Phase 64
6.3 Clinical Trials by Trial Status 65
6.4 Clinical Trials Mapping by Sponsors 66
6.5 Clinical Trials Mapping by Prominent Sponsors 67
6.6 Participants in Therapeutic Clinical Trials Companies 68
7 Irritable Bowel Syndrome (IBS) Therapeutics: Strategic Assessment 69
7.1 Key Events Impacting the Future Market 69
7.2 IBS Therapeutics: Implications for Future Market Competition 70
7.1 Key Events Impacting the Future Market 69
7.2 IBS Therapeutics: Implications for Future Market Competition 70
8 Irritable Bowel Syndrome (IBS) Therapeutics: Future Players 72
8.1 Introduction 72
8.2 Company Profiles 73
8.2.1 Ironwood Pharmaceuticals and Forest Laboratories 73
8.2.2 Tioga Pharmaceuticals 74
8.2.3 Salix Pharmaceuticals 75
8.2.4 Rottapharm SpA 77
8.2.5 Other Companies in the IBS Therapeutics Market 79
8.1 Introduction 72
8.2 Company Profiles 73
8.2.1 Ironwood Pharmaceuticals and Forest Laboratories 73
8.2.2 Tioga Pharmaceuticals 74
8.2.3 Salix Pharmaceuticals 75
8.2.4 Rottapharm SpA 77
8.2.5 Other Companies in the IBS Therapeutics Market 79
9 Irritable Bowel Syndrome (IBS) Therapeutics: Licensing and Partnership Deals 81
10 Irritable Bowel Syndrome (IBS) Therapeutics: Appendix 87
10.1 Market Definitions 87
10.2 Abbreviations 87
10.3 Research Methodology 88
10.3.1 Coverage 88
10.3.2 Secondary Research 89
10.3.3 Forecasting 89
10.3.4 Primary Research 92
10.3.5 Expert Panel Validation 92
10.4 Contact Us 92
10.5 Disclaimer 92
10.6 Bibliography 93
10.1 Market Definitions 87
10.2 Abbreviations 87
10.3 Research Methodology 88
10.3.1 Coverage 88
10.3.2 Secondary Research 89
10.3.3 Forecasting 89
10.3.4 Primary Research 92
10.3.5 Expert Panel Validation 92
10.4 Contact Us 92
10.5 Disclaimer 92
10.6 Bibliography 93
List of Tables
Table 1: IBS Therapeutics, Prevalence, 2010 9
Table 2: IBS Therapeutics Market, Global, Revenue ($m), 20052010 16
Table 3: IBS Therapeutics Market, Global, Forecast ($m), 20102018 17
Table 4: IBS Therapeutics Market, The US, Revenue ($m), 20052010 18
Table 5: IBS Therapeutics Market, The US, Forecasts ($m), 20102018 20
Table 6: IBS Therapeutics Market, France, Revenue ($m), 20052010 21
Table 7: IBS Therapeutics Market, France, Forecasts ($m), 20102018 22
Table 8: IBS Therapeutics Market, Germany, Revenue ($m), 20052010 23
Table 9: IBS Therapeutics Market, Germany, Forecasts ($m), 20102018 24
Table 10: IBS Therapeutics Market, Italy, Revenue ($m), 20052010 25
Table 11: IBS Therapeutics Market, Italy, Forecasts ($m), 20102018 26
Table 12: IBS Therapeutics Market, Spain, Revenue ($m), 20052010 27
Table 13: IBS Therapeutics Market, Spain, Forecasts ($m), 20102018 28
Table 14: IBS Therapeutics Market, The UK, Revenue ($m), 20052010 29
Table 15: IBS Therapeutics Market, The UK, Forecasts ($m), 20102018 30
Table 16: IBS Therapeutics Market, Japan, Revenue ($m), 20052010 31
Table 17: IBS Therapeutics Market, Japan, Forecasts ($m), 20102018 32
Table 18: IBS Therapeutics, Lotronex, Five Efficacy Studies in Women 43
Table 19: IBS Therapeutics, Major Marketed Products, 2011 48
Table 20: IBS Therapeutics, NDA Filed, 2011 50
Table 21: IBS Therapeutics, Phase III Clinical Pipeline, 2011 50
Table 22: IBS Therapeutics, Phase II/Phase III Clinical Pipeline, 2011 51
Table 23: IBS Therapeutics, Phase II Clinical Pipeline, 2011 51
Table 24: IBS Therapeutics, Phase I Pipeline, 2011 51
Table 25: IBS Therapeutics, Preclinical Pipeline, 2011 52
Table 26: IBS Therapeutics Discovery Pipeline, 2011 52
Table 27: IBS Therapeutics, Other Promising Mechanisms of Action 54
Table 28: IBS Therapeutics Most Promising Drugs Under Clinical Development, 2011 57
Table 29: IBS Therapeutics Clinical Trials by Country, 2011 63
Table 30: IBS Therapeutics Clinical Trials by Phase, 2011 64
Table 31: IBS Therapeutics Clinical Trials by Status (%), 2011 65
Table 32: IBS Therapeutics Overall Sponsors (%), 2011 66
Table 33: IBS Therapeutics Prominent Sponsors, 2011 67
Table 34: IBS Therapeutics Top Companies Participating in Therapeutics Clinical Trials, 2011 68
Table 35: Ironwood Pharmaceuticals Gastrointestinal Disorders Pipeline Portfolio, 2011 73
Table 36: Ironwood Pharmaceuticals IBS Pipeline Products, 2011 74
Table 37: Ironwood Pharmaceuticals Deals, 2010-11 74
Table 38: Tioga Pharmaceuticals Gastrointestinal Disorders Pipeline Portfolio, 2011 75
Table 39: Tioga Pharmaceuticals IBS Pipeline Products, 2011 75
Table 40: Tioga Pharmaceuticals Deals, 2010-11 75
Table 41: Salix Pharmaceuticals Gastrointestinal Disorders Pipeline Portfolio, 2011 76
Table 42: Salix Pharmaceuticals IBS Pipeline Portfolio, 2011 76
Table 43: Salix Pharmaceuticals Deals, 2010-11 77
Table 44: Rottapharm SpA Gastrointestinal Disorders Pipeline Portfolio, 2011 78
Table 45: Rottapharm SpA IBS Pipeline Portfolio, 2011 78
Table 46: Rottapharm SpA Deals, 2009-11 78
Table 47: IBS Therapeutics Market, Future Players 79
Table 48: IBS Therapeutics, Global, Deals 81
List of Figures
Figure 1: IBS Therapeutics, Classification 7
Figure 2: IBS Therapeutics, Percentage of Men and Women with Severe IBS 8
Figure 3: IBS Therapeutics, IBS-Subtype Percentage Breakup 8
Figure 4: IBS Therapeutics, Relation Between Pathological Factors and Development 10
Figure 5: IBS Therapeutics, Diagnostic Algorithm 11
Figure 6: IBS Therapeutics, Diagnostic Criteria (Rome III) 12
Figure 7: IBS Therapeutics, Tests Used for Diagnosis 12
Figure 8: IBS Therapeutics Market, Global, Revenue ($m), 20052010 16
Figure 9: IBS Therapeutics Market, Global, Forecast ($m), 20102018 17
Figure 10: IBS Therapeutics Market, The US, Revenue ($m), 20052010 18
Figure 11: IBS Therapeutics Market, The US, Forecast ($m), 20102018 19
Figure 12: IBS Therapeutics Market, France, Revenue ($m), 20052010 21
Figure 13: IBS Therapeutics Market, France, Forecast ($m), 20102018 22
Figure 14: IBS Therapeutics Market, Germany, Revenue ($m), 20052010 23
Figure 15: IBS Therapeutics Market, Germany, Forecast ($m), 20102018 24
Figure 16: IBS Therapeutics Market, Italy, Revenue ($m), 20052010 25
Figure 17: IBS Therapeutics Market, Italy, Forecast ($m), 20102018 26
Figure 18: IBS Therapeutics Market, Spain, Revenue ($m), 20052010 27
Figure 19: IBS Therapeutics Market, Spain, Forecast ($m), 20102018 28
Figure 20: IBS Therapeutics Market, The UK, Revenue ($m), 20052010 29
Figure 21: IBS Therapeutics Market, The UK, Forecast ($m), 20102018 30
Figure 22: IBS Therapeutics Market, Japan, Revenue ($m), 20052010 31
Figure 23: IBS Therapeutics Market, Japan, Forecast ($m), 20102018 32
Figure 24: IBS Therapeutics, Constipation Predominant IBS (IBS-C), Opportunity and Unmet Need, 2011 35
Figure 25: IBS Therapeutics, Diarrhea Predominant IBS (IBS-D), Opportunity and Unmet Need, 2011 36
Figure 26: IBS Therapeutics, Alternating Form IBS (IBS-A), Opportunity and Unmet Need, 2011 37
Figure 27: IBS Therapeutics, Constipation Predominant IBS (IBS-C), Strategic Competitor Assessment, 2011 40
Figure 28: IBS Therapeutics, Diarrhea Predominant IBS (IBS-D), Strategic Competitor Assessment, 2011 40
Figure 29: IBS Therapeutics, Alternating Form IBS (IBS-A), Strategic Competitor Assessment, 2011 41
Figure 30: IBS Therapeutics Pipeline by Phase of Clinical Development, 2011 50
Figure 31: IBS Therapeutics, Clinical Pipeline by Mechanism of Action 53
Figure 32: IBS Therapeutics, Technology Trends Analytical Framework, 2011 55
Figure 33: IBS Therapeutics, Technology Trends Analytical Framework, Description, 2011 56
Figure 34: IBS Therapeutics Clinical Trials by Country, 2011 63
Figure 35: IBS Therapeutics Clinical Trials by Phase (%), 2011 64
Figure 36: IBS Therapeutics Clinical Trials by Status (%), 2011 65
Figure 37: IBS Therapeutics Overall Sponsors (%), 2011 66
Figure 38: IBS Therapeutics Prominent Sponsors (%), 2011 67
Figure 39: IBS Therapeutics Participants in Therapeutic Clinical Trials - Companies, 2011 68
Figure 40: IBS Therapeutics Market, Key Events Impacting the Future Market, 2011 69
Figure 41: Implications for Future Market Competition in the IBS Market, 2011 70
Figure 42: IBS Therapeutics Market, Pipeline by Company, 2011 72
Figure 43: GlobalData Market Forecasting Model 91
Upcoming Reports:
|
Active, Smart And Intelligent Packaging Market - Global Industry Analysis, Market Size, Market Share, Growth And Forecast, 2012 - 2018
By - Transparency Market Research
The active, smart and intelligent packaging (advanced packaging) refers to the packaging system used in pharmaceuticals, food and other products. Advanced packaging is rapidly replacing the traditional packaging system as it improves the visual appearance of the products by interacting internally and externally with the environment.
The global food packaging industry has witnessed significant growth in the last five years due to rising urban lifestyles and rising global population. North America is the largest regional market in the global advanced packaging market...
|
|
Dermatological Diagnostics And Therapeutics Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
By - Transparency Market Research
The Dermatological diagnostics and therapeutics market is expected to grow steadily during the forecast period driven by increase in psoriasis market that is expected to boost competition among the existing products with more emerging therapies. Acne is the largest market segment of the dermatological diagnostics market accounting for 28.7% of the total therapeutics market followed by psoriasis (26.4%), rosacea (14.9%), and atopic dermatitis (9%).
Many new players are emerging in this market as a result of a number of growth opportunities provided by this market, thus...
|
|
Chelating Agents Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Chelating agents are organic compounds that form co-ordinate chemical bonds. The compound that forms the bond is called a chelate. Chelating agents have different applications in different industrial markets such as enzyme deactivation, textile dyeing, bacteriocides and water softening.
The global chelating agent’s market volume is expected to reach more than 5 million tonnes in 2018. The market is growing rapidly due to factors such as innovative use of chelating agents and the increase in demand of cleaners and detergents.
The chelating...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Latest Reports
- The Future of the Wine Market in Indonesia to 2017
- The Future of the Wine Market in Hungary to 2017
- The Future of the Wine Market in Hong Kong to 2017
- The Future of the Wine Market in Greece to 2017
- The Future of the Wine Market in Finland to 2017
- The Future of the Wine Market in Egypt to 2017
- The Future of the Wine Market in Denmark to 2017
- The Future of the Wine Market in Czech Republic to 2017
- The Future of the Wine Market in the United Kingdom to 2017
- Switzerland Quarterly Beverage Tracker Report Q1 2013
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
